The launch of Pelthos Therapeutics and the appointment of an experienced CEO like Scott Plesha are positive developments for Ligand Pharmaceuticals. These steps, aimed at commercializing ZELSUVMI, a novel drug with significant market potential, are likely to be viewed positively by investors. The strategic move to commercialize ZELSUVMI in partnership, following Ligand's successful strategy of creating value through equity and royalty rights, further supports a positive outlook. However, the actual market impact will depend on the execution of these plans and the market's reception of ZELSUVMI upon launch.